The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE).
 
Alexandra Torres
No Relationships to Disclose
 
Megan Aaron
No Relationships to Disclose
 
Lia White
No Relationships to Disclose
 
Kurt D'Andrea
No Relationships to Disclose
 
Vivek Narayan
Honoraria - Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca; Exelixis; Janssen Oncology; Merck; Myovant Sciences; Pfizer/EMD Serono; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Tmunity Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Hayley Michelle Knollman
No Relationships to Disclose
 
Angela R. Bradbury
Consulting or Advisory Role - AstraZeneca; Merck
Research Funding - AstraZeneca/Merck (Inst)
 
Nadine M. Tung
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
 
Mark E. Robson
Consulting or Advisory Role - Change HealthCare
Research Funding - AstraZeneca (Inst); Merck (Inst); Pfizer (Inst); Zenith Pharmaceuticals (Inst)
Other Relationship - AstraZeneca; Clinical Care Options; Clinical Education Alliance; MJH Healthcare Holdings, LLC; MyMedEd; Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Artios; Daiichi Sankyo; Epic Sciences; Merck; Pfizer; Tempus; Zenith Pharmaceuticals
 
Katherine Nathanson
Consulting or Advisory Role - Merck
 
Susan M. Domchek
Honoraria - AstraZeneca; GlaxoSmithKline
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst)
 
Payal Deepak Shah
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Johnson & Johnson (I); Merck (I); Novartis (I); Novo Nordisk; Novo Nordisk (I); Pfizer (I)
Consulting or Advisory Role - Daiichi Sankyo; Gilead Sciences
Research Funding - AstraZeneca (Inst); Zenith Epigenetics (Inst)